Now Japan’s Eisai, which has invested £1.3 billion in the UK including a factory in Hatfield, has given the strongest indication yet that it might take its money elsewhere. This is despite the ...

Manufacturing of this drug will now take place at Eisai’s £100 million, purpose-built EMEA and Russia headquarters in Hatfield, UK. Fycompa will be supplied across the world from this site ...

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from ...